An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 ... for a 0.25-milligram starter dose and 42,960 yen for a 2.4 mg dose, Novo said.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with medication, and he also has a history of recurrent prostate cancer. My mother ...

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.